Endurant Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Endurant Capital Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,102,280	Closed	-$14.3M	–	71
2022 Q3	$14.3M	Buy	+1,102,280	New	+$15.3M	4.66%	4
2020 Q2	–	Sell	-156,120	Closed	-$2.37M	–	72
2020 Q1	$2.37M	Buy	+156,120	New	+$2.83M	1.07%	26
2019 Q4	–	Sell	-92,273	Closed	-$1.59M	–	67
2019 Q3	$1.59M	Sell	92,273 -840,694	-90%	-$14.5M	0.57%	31
2019 Q2	$16.5M	Buy	932,967 +495,531	+113%	+$9.02M	6.51%	1
2019 Q1	$8.91M	Buy	+437,436	New	+$8.8M	3.52%	9

Other funds holding TAK

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Endurant Capital Management's TAK Position: Q4 2022 in Review

Endurant Capital Management sold out of Takeda Pharmaceutical (TAK) in Q4 2022, closing a stake of 1,102,280 shares — an estimated $14.3M sold.

Endurant Capital Management first reported a position in TAK in Q1 2019 and held it in 5 quarters. The position peaked at $16.5M in Q2 2019. 282 funds tracked by Wall St. Rank hold TAK as of Q4 2022.

Endurant Capital Management reported no remaining Takeda Pharmaceutical position as of Q4 2022 after selling out during the quarter.
Endurant Capital Management sold 1,102,280 Takeda Pharmaceutical shares in Q4 2022, an estimated $14.3M.
Endurant Capital Management first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 5 quarters.
Endurant Capital Management's Takeda Pharmaceutical position peaked at $16.5M in Q2 2019.
282 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2022.

Based on Endurant Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.